ClinicalTrials.gg
CompletedNCT06754228Updated Nov 13, 2026

Acute Immune Modulation by Probiotic Strain

An interventional study of Probiotic Agent and Probiotic Agent in Immune Surveillance, sponsored by Natural Immune Systems Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Natural Immune Systems Inc · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Clinical proof-of-concept study, comparing the acute immune impacts of 3 doses of a probiotic strain to a placebo.

The initial four-participant module evaluated all 3 planned probiotic doses. The subsequent eight-participant module evaluated only the lowest and highest doses; consequently, the intermediate dose was administered to four participants only.

This study involved twelve participants, composed of healthy adults, who consumed a placebo and different doses of the probiotic at different times. Testing for immune status and cytokine levels was conducted to determine the acute impact of the probiotic on immune function when compared to a placebo.

Read the detailed description

Clinical proof-of-concept study comparing the acute immune effects of different doses of a probiotic compared to a placebo. The probiotic strain is characterized as Bacillus coagulans JBI-YZ6.3 (BC4U).

12 subjects participated in a placebo-controlled, escalating dose, cross-over study design, wherein they consumed placebo, dose 1, (dose 2: only initial module of N=4), and dose 3, each separated by a 1-week washout period.

Blood samples were taken 1 hour after participants arrived; the dose was then administered. Samples were taken 1 hour, 2 hours, and 3 hours following administration.

A series of immune panels were used to determine the acute impacts on immune surveillance, immune cell activation status, immune cell priming, and cytokine profiles.

02

Conditions studied

  • Immune Surveillance
03

In context

Lead sponsor

Natural Immune Systems Inc is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults;
  • Age 18-75 years (inclusive);
  • Veins easy to see in one or both arms (to allow for the multiple blood draws);
  • Willing to comply with study procedures, including:

    • Maintaining a consistent diet and lifestyle routine throughout the study,
    • Consistent habit of bland breakfasts on days of clinic visits,
    • Abstaining from exercising and nutritional supplements on the morning of a study visit,
    • Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit;
    • Abstaining from music, candy, gum, computer/cell phone use, during clinic visits.

Exclusion criteria

Exclusion Criteria:

  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder);
  • Taking anti-inflammatory medications on a daily basis;
  • Currently experiencing intense stressful events/ life changes;
  • Currently in intensive athletic training (such as marathon runners);
  • Currently taking antipsychotic medications such as clozapine, Risperdal, Abilify, Zyprexa or Seroquel;
  • An unusual sleep routine (examples: working graveyard shift, irregular routine with frequent late nights, studying, partying);
  • Unwilling to maintain a constant intake of supplements over the duration of the study;
  • Anxiety about having blood drawn;
  • Pregnant, nursing, or trying to become pregnant;
  • Known food allergies related to ingredients in active test product or placebo.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Experimental Group A

    Crossover study: Participants consumed placebo on the first clinic visit, a low dose of the probiotic on the second clinic visit, (a medium dose of the probiotic on the third clinic visit (only the first 4 participants), and a high dose of the probiotic on the final clinic visit. Each clinic visit was separated by at least 1 week wash-out period.

    Dietary Supplement: Probiotic Agent

Interventions

  • Dietary supplementProbiotic Agent

    Bacillus coagulans JBI-YZ6.3 (BC4U)

  • Dietary supplementProbiotic Agent

    An escalating dose cross-over design: Participants are fed 0 mg, 100 mg, 200 mg, and 400 mg on different clinic visits.

06

What researchers measure

Primary outcomes

  1. Immune communication

    Changes in serum cytokine levels

    Time frame: 3 hours

Secondary outcomes

  1. Immune surveillance and alertness

    Changes in immune cell trafficking and status of immune cell alertness, ie. the changes in immune cell populations and activation status following consumption: Numbers of CD3- CD56+ NK cells in blood Numbers of CD3+ CD56+ NKT cells in blood Numbers of CD3+ CD56- T cells in blood Numbers of cells positive for CD25 Numbers of cells positive for CD69

    Time frame: 3 hours

Other outcomes

  1. Immune responsiveness

    Ex vivo immune challenges, documenting the capabilities of anti-bacterial and anti-viral immune responses: Cytokine levels in 24-hour culture supernatants of ex vivo immune cell cultures in unchallenged cultures Cytokine levels in 24-hour culture supernatants of ex vivo immune cell cultures in lipopolysaccharide-inflamed cultures Cytokine levels in 24-hour culture supernatants of ex vivo immune cell cultures in Poly I:C challenged cultures

    Time frame: 3 hours

07

Study locations

1 site
  • NIS Labs
    Klamath Falls, Oregon 97601, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Sep 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Dec 31, 2024
StartActual
Nov 13, 2024
Primary completionActual
Sep 30, 2025
CompletionActual
Dec 23, 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, description and arm descriptions
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06754228
Lead sponsor
Natural Immune Systems Inc
Collaborators
Jeneil Biotech Inc.
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Nov 13, 2024
Primary completion
Sep 30, 2025
Completion
Dec 23, 2025
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion